Your Position: Home > Journal List > China Medicine > Paper

Prognosis of the maintenance therapy with different doses of cytarabine in elderly patients with acute myelogenous leukemia

( views:388, downloads:0 )
Author:
GUO Zhi(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
HE Xue-peng(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
CHEN Hui-ren(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
LIU Xiao-dong(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
ZHANG Yuan(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
CHEN Peng(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
YANG Kai(Department of Hematology,General Hospital of Beijing Military Commonding Region,Beijing 100700,China)
Journal Title:
China Medicine
Issue:
Volume 07, Issue 11, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.11.020
Key Word:
Acute myeloid leukemia;Elderly;Cytarabine;Maintenance treatment;Survival rate

Abstract: Objective To study the efficacy and safety of different doses of cytarabine maintenance therapy in elderly patients with acute myeloid leukemia (AML).Methods Thirty-two cases achieved remission after induction chemotherapy in elderly patients with acute myeloid leukemia (AML)from January 2005 to January 2010in General Hospital of Beijing Military Region.They were randomly divided into treatment group A(n =12),the treatment group B(n =10) and the treatment group C (n =10).After achieving complete remission,the patients in three groups were treated with different doses of a single drug (0.5 g/Ara-C,0.5 g/m2 and 1 g/m2,intravenous injection) to maintain the consolidation therapy.The courses were 6 to 8 courses,maintaining for 1-2 years.Results Treatment-related mortality rate was 16.7% (2/12),10.0% (1/10) and 20.0% (2/10) in treatment group A,B and C.Relapse-related mortality was 41.7% (5/12),50.0% (5/10) and 40.0% (4/10) ; median survival was 15.8 (5-60) months,16.2 (6-60) months and 15.7 (6-60) months ; the 2-year overall survival rate was 41.7%,40.0% and 40.0%.Conclusions Maintenance therapy of different doses cytarabine in elderly patients with acute myeloid leukemia shows no significant survival differences.It increases dose treatment-related complications and does not increase the overall long-term survival rate.

  • [1]郭智,谭晓华,刘晓东,等.大剂量阿糖胞苷治疗急性髓系白血病的疗效分析.中华内科杂志,2010,49(3):250-251.
  • [2]郭智,谭晓华,陈惠仁,等.中剂量阿糖胞苷强化治疗老年急性髓系白血病疗效观察.中华临床医师杂志:电子版,2009,3(12):2016-2020.
  • [3]张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:106-115.
  • [4]Stone RM.The difficult problem of acute myeloid leukemia in the older adult.CA Cancer J Clin,2002,52(6):363-371.
  • [5]Farag SS,Ruppert AS,Mrózek K,et al.Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype:a cancer and leukemia group B study.J Clin Oncol,2005,23 (3):482-493.
  • [6]B(o)hm A,Piribauer M,Wimazal F,et al.High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML:a single center experience.Leuk Res,2005,29 (6):609-615.
  • [7]郭智,刘晓东,阮新建,等.恶性血液病患者化疗后大剂量应用白细胞介素-2的疗效观察.白血病·淋巴瘤,2008,17(2):123-124.
  • [8]朱娟,吕晓毅,李艳,等.口服4-去甲氧柔红霉素联合化疗治疗老年急性髓系白血病.中国医药,2006,1(1):58.
  • [9]张峰,贾金海.大剂量阿糖胞苷与甲氨蝶呤化疗对肾损害的探讨.中国医药,2006,1(2):87-88.
  • [10]董海林,杨常建,陈晓亮.FLAG方案治疗难治或复发急性髓系白血病26例临床观察.中国基层医药,2010,17(15):2050-2052.
  • [11]王茫桔,马明信,王颖,等.CAG预激方案治疗急性髓细胞性白血病疗效分析.中国综合临床,2010,26(3):285-286.
  • [12]郭智,楼金星,谭晓华.砷剂联合CAG方案治疗难治性急性髓系白血病18例疗效观察.中国煤炭工业医学杂志,2007,10(6):656.
  • [13]方洁.粒细胞-集落刺激因子配合小剂量阿糖胞苷治疗低增生性急性白血病8例.中国综合临床,2008,24(13):24-25.
  • [14]刘文,李峰敏,郭嫒嫒,等.CAG方案治疗难治、复发性急性髓系白血病的临床疗效.中国煤炭工业医学杂志,2006,9(4):362-363.
  • [15]李泉,藜纬明,邹萍.FLAG方案治疗难治或复发急性白血病的临床研究.中国综合临床,2007,23(11):982-984.
  • [16]段超.FLAG方案治疗难治和复发性急性髓系白血病疗效观察.疑难病杂志,2009,8(3):173-174.
  • [17]赵立云.CAG/HAG方案联合中药治疗老年急性髓系白血病疗效观察.河北医科大学学报,2010,31 (7):782-785.
  • [18]Martin MG,Abboud CN.Induction therapy for elderly patients with acute myeloid leukemia.Blood Rev,2008,22 (6):311-320.
  • [19]R(o)llig C,Thiede C,Gramatzki M,et al.A novel prognostic model in elderly patients with acute myeloid leukemia:results of 909 patients entered into theprospective AML96 trial.Blood,2010,116 (6):971-978.
  • [20]于晓明,唐桂华,李秀娟.HAG方案治疗低增生性及老年性急性髓细胞白血病疗效观察.中国医药,2006,1 (7):394-395.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn